Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
Guerrieri S, Bucca C, Nozzolillo A, Genchi A, Zanetta C, Cetta I, Rugarli G, Gattuso I, Azzimonti M, Rocca MA, Moiola L, Filippi M; SanRaf MS Study Group.
Guerrieri S, et al. Among authors: cetta i.
Eur J Neurol. 2023 Sep;30(9):2859-2864. doi: 10.1111/ene.15891. Epub 2023 Jun 5.
Eur J Neurol. 2023.
PMID: 37227923